Pfizer's once-daily Lyrica trial fails to meet goal
(Reuters) - Pfizer Inc said on Friday a late-stage trial of a once-a-day formulation of its drug pregabalin did not significantly reduce the frequency of some types of seizures in patients with epilepsy.
Pfizer's biggest product, sold under the brand name Lyrica, is used to treat epilepsy when given several times a day in combination with other drugs. The drug, with $4 billion in annual sales, is more widely used to treat nerve pain.
Pfizer said the lack of a statistically significant improvement may have been due to a higher-than-expected response among patients taking the placebo.
The study was the first of three trials testing the drug as a once-a-day therapy. The company is also testing it in patients with fibromyalgia and some types of nerve pain, for which it is also approved in its immediate-release formulation.
(Reporting By Toni Clarke; Editing by Gerald E. McCormick and Grant McCool)
- Cortege departs to take Mandela's body to lie in state |
- U.S. Mega Millions lottery up to $344 million, fourth biggest in its history
- UPDATE 1-U.S. Mega Millions lottery up to $344 million, fourth biggest in its history
- Uruguay becomes first country to legalize marijuana trade
- Ukrainian riot police clash with protesters in Kiev square
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more